Bradykinin is a potent vasodilator that is formed by the activation of the kallikrein-kinin system. We and others have shown that bradykinin increased during hemodialysis; however, the role of bradykinin in dialysis-induced hypotension (DIH) has not been evaluated. Preliminary results from a pilot clinical trial showed that bradykinin B2 receptor blockade with icatibant prevents excessive blood pressure during hemodialysis. Thus, in this study, we will test the overarching hypothesis that blockade plasma kallikrein with lanadelumab would ameliorate the reduction of blood pressure during hemodialysis in patients who are prone to DIH. For this purpose, we will conduct a parallel arm, double-blind placebo-controlled trial, using lanadelumab to evaluate the occurrence of

开始日期2022-07-27

申办/合作机构

Vanderbilt University Medical Center

100 项与拉那利尤单抗相关的临床结果

登录后查看更多信息

100 项与拉那利尤单抗相关的转化医学

登录后查看更多信息

100 项与拉那利尤单抗相关的专利（医药）

登录后查看更多信息

175

项与拉那利尤单抗相关的文献（医药）

2026-10-01·World Allergy Organization Journal

Long-term prophylaxis for hereditary angioedema: Navigating the switch between therapies

Review

作者: Cancian, Mauro ; Guilarte, Mar ; Magerl, Markus ; Busse, Paula J ; Bouillet, Laurence ; Craig, Timothy ; Cohn, Danny M ; Reshef, Avner ; Radojicic, Cristine ; Riedl, Marc A ; Lumry, William R ; Tachdjian, Raffi ; Bernstein, Jonathan A ; Banerji, Aleena

Long-term prophylactic treatments (LTPs) are a major component of disease management for patients with hereditary angioedema (HAE). Patients with HAE experience considerable disease burden, as the frequent, unpredictable, and potentially life-threatening nature of HAE attacks negatively impacts patients' quality of life. LTPs aim to mitigate HAE symptoms by reducing HAE attack frequency and severity, leading to improved disease management and quality of life. As the treatment landscape has recently expanded with the addition of approved LTPs (namely, garadacimab and donidalorsen in 2025), the decision to switch between therapies is becoming increasingly common in clinical practice, and physicians and patients must carefully navigate these treatment transitions to minimize the risk of breakthrough HAE attacks and other safety concerns. Across clinical studies, treatment switching was reported for a variety of reasons, including suboptimal efficacy or frequent breakthrough attacks, safety and adverse events, family planning, treatment burden (including the LTP dosing frequency and route of administration), and drug costs and access. As these treatment options have unique mechanisms of action, durations of effect, and drug clearance rates, clinicians must carefully evaluate approaches for patients to safely switch between therapies while aiming to minimize the risk of breakthrough attacks due to lapses in prophylaxis. This review summarizes the current clinical data available in patients who have switched between first-line LTPs (namely, C1 inhibitor, lanadelumab, and berotralstat), recently approved LTPs garadacimab and donidalorsen, and second-line LTPs (androgens and antifibrinolytics) and it aims to inform health care providers as they navigate this complex treatment landscape. Clinical data available that directly evaluate or compare switching strategies between LTPs are limited, highlighting the need for further prospective studies to better characterize treatment outcomes and guide switching treatments for patients with HAE.

2026-10-01·World Allergy Organization Journal

Long-term prophylactic treatment and related real-world outcomes of patients with hereditary angioedema in Germany: A retrospective analysis of German claims and medical chart data

Article

作者: Wilke, Thomas ; Maywald, Ulf ; Greve, Jens ; Donatz, Verena ; Jülich, Fabian ; Picker, Nils

Background:

Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent swelling episodes that are potentially life threating and substantially impair quality of life. This study aimed to generate real-world evidence on the utilization of long-term prophylaxis (LTP), residual disease burden, and economic outcomes among patients with HAE in Germany.

Methods:

This retrospective cohort study examined LTP patterns and associated real-world outcomes using 2 anonymized German statutory health insurance datasets (AOK PLUS and GWQ) and a medical chart review (MCR) from 1 specialized HAE center. Claims datasets included patients initiating LTP between 2019 and 2023. The MCR provided complementary clinical information and was used to assess the plausibility of prescription-based estimates for attack frequency. Outcomes included LTP treatment sequences, HAE attacks requiring on-demand treatment (ODT), healthcare resource utilization and direct cost.

Results:

Across the claims datasets, 77 patients initiated first-line LTP: 30 (39.0%) with intravenous C1 esterase inhibitors (C1INH IV), 24 (31.2%) with lanadelumab, 16 (20.8%) with subcutaneous C1INH, and 7 (9.1%) with berotralstat. During follow-up, 27 patients (35.1%) switched therapy, most commonly from C1INH IV to lanadelumab. Despite prophylaxis, 64% of patients experienced at least 1 HAE attack requiring ODT, while 36% remained attack-free during the first year after LTP start. Median time to first treated attack ranged from 114 to 132 days. Prescription-based attack estimates were generally consistent with physician-documented attack frequencies but tended to yield slightly higher attack rates. Annual healthcare costs were driven primarily by outpatient medications, averaging €233,190 and €206,392 per person-year in the AOK PLUS and GWQ cohorts, respectively.

Conclusion:

This study provides real-world evidence on LTP use in Germany and demonstrates that a substantial proportion of patients continues to experience treated attacks despite prophylaxis. These findings highlight the importance of ongoing monitoring, individualized treatment optimization, and continued access to ODT.

2026-09-01·The journal of allergy and clinical immunology. Global

Sebetralstat for breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis in KONFIDENT-S

Article

作者: Melamed, Isaac ; Farkas, Henriette ; Yea, Christopher M ; Bajcic, Paolo ; Honda, Daisuke ; Bouillet, Laurence ; Ohmura, Kazumasa ; Martinez-Saguer, Inmaculada ; Riedl, Marc A ; Kiani-Alikhan, Sorena ; Cancian, Mauro ; Zanichelli, Andrea ; Bara, Noemi ; Cohn, Danny M ; Geng, Bob ; Wedner, H James ; Kinaciyan, Tamar ; Rehman, Syed ; Ohsawa, Isao ; Craig, Timothy J ; Raasch, Jason P ; Busse, Paula J ; Aygören-Pürsün, Emel ; Kanarek, Henry J ; El-Shanawany, Tariq ; Manning, Michael E ; Lumry, William R ; Smith, Michael D ; Koleilat, Majed ; Li, H Henry ; Audhya, Paul K ; Fukunaga, Atsushi ; Iverson, Matthew ; Bernstein, Jonathan A ; Tachdjian, Raffi ; Chuang, Ya-Hsiu ; Soteres, Daniel F

Background:

Although long-term prophylaxis (LTP) reduces attack frequency in hereditary angioedema, patients may experience breakthrough attacks. Oral sebetralstat demonstrated favorable safety and efficacy compared with placebo in the randomized phase 3 KONFIDENT trial (NCT05259917), including in patients receiving LTP. The safety and effectiveness of sebetralstat in participants receiving LTP are being assessed in the KONFIDENT-S open-label extension study (NCT05505916).

Objective:

This interim analysis of the KONFIDENT-S study evaluated long-term safety and effectiveness of oral sebetralstat 600 mg for attacks of hereditary angioedema with C1-inhibitor deficiency in participants receiving LTP with lanadelumab, berotralstat, or C1 inhibitor.

Methods:

Efficacy end points included times to beginning of symptom relief, reduction in severity, and complete attack resolution.

Results:

As of September 14, 2024, 35 participants receiving LTP experienced a mean ± standard deviation of 1.7 ± 1.5 attacks per month and treated 382 attacks with sebetralstat (1.3 ± 1.1 sebetralstat-treated attacks per month). Median (interquartile range) time from attack recognition to sebetralstat administration was 6 (1-40) minutes; time to beginning of symptom relief was 1.3 (0.8 to 3.8) hours, time to reduction in severity was 4.2 (1.3 to >12) hours, and time to complete attack resolution was 14.8 (4.6 to >24) hours. Effectiveness was similar for participants receiving berotralstat, lanadelumab, or C1 inhibitor. No serious or severe treatment-related treatment-emergent adverse events were reported.

Conclusion:

Sebetralstat was well tolerated and enabled early on-demand treatment of attacks in patients with hereditary angioedema with C1-inhibitor deficiency receiving LTP. Treatment of breakthrough attacks with sebetralstat resulted in rapid symptom relief, reduction in attack severity, and complete attack resolution, regardless of LTP mechanism of action.

204

项与拉那利尤单抗相关的新闻（医药）

2026-10-16

·药物导图

Andembry®（garadacimab-gxii / 加达西单抗）综合知识图谱

摘要（约330字） Andembry®（garadacimab-gxii，中文通用名加达西单抗）是 CSL Behring 完全自主研发的全人源IgG4λ 单克隆抗体，特异性结合并抑制活化凝血因子XIIa（FXIIa）催化结构域，阻断接触激活通路→前激肽释放酶活化→缓激肽生成这一 HAE 病理级联的最上游步骤，用于常规预防HAE 发作，不是急性发作抢救药。 FDA 于 2025-06-16 批准，适用于12 岁及以上成人和青少年 HAE（I 型/II 型 C1-INH 缺乏）患者的发作预防；欧盟委员会2025-02-13 批准，标签口径一致。给药为第 1 天皮下 400 mg 负荷（两针 200 mg），之后每月 200 mg 一次，可用预充自动注射笔，患者经培训后自行注射。 VANGUARD（NCT04656418，n=64）主要终点：6 个月内每月 HAE 发作率较安慰剂相对下降 89.2%（0.22 vs 2.01 次/月），62% 治疗组患者全程无发作，发作中位数降至 0 。美标签常见不良反应仅鼻咽炎和腹痛（≥7%），Contraindications 和 Warnings 均写 None；欧版因含脯氨酸和聚山梨酯 80，列辅料超敏为禁忌。中国状态：CDE 受理号 JXSS2500100，2025-07-17 承办受理，本图检索范围内未确认NMPA 正式获批上市。1）基础标识域（Identity Domain） INN：garadacimab-gxii；中文通用名：加达西单抗注射液。商品名：Andembry®（美/欧/日/英/澳等）；暂无官方中文商品名统一口径，国内申报用“加达西单抗注射液”。药物类型：重组全人源IgG4λ 单克隆抗体，活化因子 XII（FXIIa）抑制剂，生物制剂（BLA/MAA 路径）。表达体系：CHO 细胞重组表达。规格：200 mg / 1.2 mL（约 167 mg/mL），单剂量预充自动注射笔（autoinjector）或预充安全针式注射器。性状：无菌、无防腐剂、微乳光至澄清、棕黄至黄色溶液，pH≈6.1，渗透压≈470 mOsm/kg 。辅料关键点：每支含脯氨酸19.3 mg + 聚山梨酯 80 0.24 mg（欧版 SPC 列明；美版标签以完整处方为准）。持证/生产：CSL Behring（美标签 Manufactured for CSL Behring GmbH, Marburg；Manufactured by CSL Behring LLC, King of Prussia）。美国批准：2025-06-16，BLA 路径，Initial U.S. Approval 2025 。欧盟批准：2025-02-13 欧委会决定（EC 公告日 2025-02-13）。其他已批地区：英国、日本、澳大利亚、瑞士、阿联酋等（CSL 新闻稿口径）。中国状态：CDE 受理号 JXSS2500100，2025-07-17 承办，进口治疗用生物制品 3.1 类，CSL Behring AG 申报——未确认NMPA 发证，以 CDE/NMPA 最新公示为准。 NDC：63833-925-01（单支）、63833-925-20（多支装）。2）核心独特卖点（Core USPs） 1.上游拦截：直接抑FXIIa，在接触激活通路“第一把火”处切断，不像激肽释放酶抑制药（如拉那利尤单抗）或 B2 受体拮抗药（如艾替班特）那样等下游介质已经生成才拦。 2.从治疗第一天起就每月一次：所有患者统一400 mg 负荷 + 200 mg Q4W 维持，不需按体重分层，不需先打几针再延间隔。 3.可居家自行注射：预充自动注射笔，厂方新闻稿称约15 秒完成，无柠檬酸盐配方；经医护培训后患者/照护者操作。 4.单臂小样本但数值强：VANGUARD 中 62% 全程无发作、发作中位数降至 0、需按需治疗的发作率相对降 91.2%、中重度发作相对降 93.6% 。 5.美标签干净：Contraindications None、Warnings None，主要只是 aPTT assay 干扰和注射部位反应——但欧版因辅料列超敏禁忌，不能把“无禁忌”当成全球统一写法。3）靶点与作用机制域（Target & MoA Domain）靶点：活化凝血因子XII（FXIIa，含 βFXIIa）催化结构域。机制链路： 1.garadacimab-gxii 结合 FXIIa 催化域 → 2.抑制FXIIa 酶活性 → 3.前激肽释放酶不被活化为激肽释放酶→ 4.缓激肽生成减少→ 5.血管通透性不升高，HAE 发作被预防。定位：接触激活（intrinsic/contact activation）通路最上游，比 C1-INH 替代、激肽释放酶抑制、B2 受体阻断都更靠前。注意边界：nC1-INH HAE（HAE with normal C1-INH，如 HAE-FXII、HAE-PLG）可能走非 FXII 依赖通路，部分亚类应答差，欧标签要求基因检测+3 个月无应答考虑停药。4）适应症与治疗定位域（Indications & Positioning） FDA 标签适应症用于12 岁及以上成人和儿童患者的遗传性血管性水肿（HAE）发作预防性处理（prophylaxis）。 EMA / 英版 SPC 适应症用于12 岁及以上成人和青少年 HAE 患者常规预防反复发作。能做什么 HAE I 型 / II 型（C1-INH 缺乏或功能异常）的长期预防。替代或补充现有预防方案：C1-INH 浓缩剂、拉那利尤单抗、艾卡拉肽、Berotralstat 等——是“多一个机制选择”，不是标签写“取代”。培训后居家每月一次，提升依从性。不能做什么（标签边界）不用于急性HAE 发作抢救（喉头水肿/腹痛发作要用 C1-INH 浓缩剂、艾替班特等急救药）。不用于<12 岁儿童（美/欧均未批；2–11 岁 3b 期数据 2026-07 读出阳性，但仅 topline，未批）。 nC1-INH HAE 疗效不确定，3 个月无应答考虑停。不是抗凝药，不用于血栓预防或治疗。定位场景适用：12 岁+ 需长期预防、想要每月一次皮下自注、能区分“预防药≠急救药”的 HAE 患者。不适用：急性发作当场、<12 岁、对脯氨酸/聚山梨酯 80 严重过敏（欧版禁忌）、nC1-INH 型且 3 个月无应答者。5）关键临床与循证域（Clinical Evidence） VANGUARD（NCT04656418）设计：全球多中心、随机、双盲、安慰剂对照、平行组，6 个月；3:2 入组。人群：64 例 12 岁+ I/II 型 HAE，入组前 2 个月≥2 次研究者确认发作；洗脱其他预防药。分组：garadacimab 400 mg 负荷 + 200 mg 每月 SC（n=39） vs 安慰剂（n=25）。主要终点（6 个月每月研究者确认发作率）：治疗组0.22 次/月 vs 安慰剂 2.01 次/月相对下降89.2%（least squares mean，p<0.001）关键次要：需按需治疗的发作率相对降91.2% 中重度发作率相对降93.6% 主要终点相关描述：62% 治疗组患者整个治疗期无发作，发作中位数降至 0 。关于“中位数降超过 99%”：是 CSL 新闻稿和若干二次解读的写法，主表以标签可核的 89.2% LS-mean 为主，不把“>99% 中位数”当主要有效率。开放标签扩展研究（OLE）中位暴露13.8 个月，长期安全性可接受，发作频率持续降低。最长约16.7 个月随访时，约 59.6% 患者保持无发作（微信稿转述，仅作补充，不进主终点表）。文献出处 Craig TJ et al., Lancet 2023;401(10382):1079–1090（VANGUARD 全文） Reshef A et al., Allergy 2024（OLE 中期分析）6）安全性与特殊人群域（Safety & Special Populations）美标签口径（FDA）禁忌：None 警告/注意事项：None 常见不良反应（≥7%）：鼻咽炎（21%，8/39）、腹痛（8%，3/39）实验室：aPTT 可延长（>1.4×ULN 约 8%）；PT/INR 偶见延长（约 15%）欧/英标签补充禁忌：对garadacimab 或任何辅料（含脯氨酸、聚山梨酯 80）严重超敏者含脯氨酸→高脯氨酸血症者禁用（罕见遗传代谢病）含聚山梨酯80→理论过敏风险注射部位反应（红斑/瘀斑/瘙痒/荨麻疹/血肿）在关键试验+OLE 合计 23 例（14%）严重超敏未在临床中观察到但理论上可发生，出现即停针+按过敏处理关键注意事项非急救药：突破发作用已批准的rescue 药（C1-INH / 艾替班特等） aPTT 干扰：本药抑FXIIa，aPTT 试剂走接触激活通路，故 aPTT 假性延长——就医/术前查凝血要主动告知在用 Andembry，避免误判血友/凝血病 nC1-INH HAE：有限数据，3 个月无应答考虑停特殊人群 <12 岁：未批，不推荐（2–11 岁 3b 期：6–11 岁 100 mg 每月、2–5 岁 100 mg 每 2 月，仅 topline 阳性，申报中）妊娠：美标签无可用数据，不建议随意用；欧标签建议避免，需个体化哺乳：不明确是否入乳，美标签无数据，欧标签建议医生评估后使用 ≥65 岁：无需调量（欧/瑞士标签）肝损：轻中度不需调量，中重度数据有限（欧版写不需调量，瑞士写有限数据）肾损：轻中度不需调量，中重度有限数据联合预防：未与拉那利尤单抗/C1-INH 长效预防药做联合研究，不推荐叠加7）药学与给药信息域（Pharmacy & Administration）推荐剂量第1 天：皮下注射 400 mg（两针200 mg，可同次不同部位）之后：每月一次200 mg SC 漏打：尽快补打（美标签写as soon as possible；瑞士标签补一句“相邻两剂至少隔 1 个月”）注射操作仅皮下：腹部（避肚脐2 cm）、大腿、上臂外侧；上臂建议照护者协助轮换部位，不反复打同一点，不打瘢痕/痣/瘀斑/红肿处预充笔或预充安全针，经医护培训后自注或照护者注厂方新闻稿：无柠檬酸配方，自动注射笔约15 秒完成冷藏取出按说明书回温（部分患者资料写约30 分钟），不微波、不热水烫、不暴晒监测与随访治疗前确认HAE 类型（I/II 型或 nC1-INH），必要时基因检测治疗中：记录每月发作次数、是否需急救药、注射部位反应 nC1-INH 患者：3 个月发作减少不充分→评估停药术前/有创检查：主动报“在用 FXIIa 单抗”→解释 aPTT 延长配伍/相互作用无专门DDI 研究；急救药（C1-INH、艾替班特）不影响本品 PK 不建议与其他长效HAE 预防药联合贮藏美标签未给具体室温时限，按包装说明书冷藏避光保存，过期弃单剂量设备，不共享、不重复使用8）注册/产业/归档域（弱引用）美国：2025-06-16 FDA 批准，BLA，Initial U.S. Approval 2025 欧盟：2025-02-13 EC 批准，SPC 写 12 岁+ 常规预防英国：MHRA 2025-01 批准（CSL 新闻口径）日本/澳洲/瑞士/阿联酋：已批，CSL 新闻稿列名中国：JXSS2500100，2025-07-17 CDE 承办受理，进口 3.1 类，未确认NMPA 正式上市研发中扩展：2–11 岁 HAE 3b 期 2026-07-27 读出阳性（6–11 岁 100 mg Q4W，2–5 岁 100 mg Q2M），CSL 称将递交扩展适应症，未批前不进适应症主表其他适应症探索：特发性肺纤维化（IPF）II 期进行中竞品定位：与Takhzyro（拉那利尤单抗，每 2 周/4 周）、Orladeyo（Berotralstat，每日口服）、C1-INH 类并列，不是替代关系，按给药频次和机制选使用边界：本图谱供变态反应科/免疫科/罕见病药学/医保准入用。数据来源于最新FDA SPL（DailyMed 2025-06 版）、EMA SP C、国内 CDE 受理进度、NMPA 最新公示。它回答“哪些 12 岁+ HAE 患者适合每月一针预防、怎么打、看到 aPTT 延长别慌”，不替代 HAE 分型检测和急性发作用药。

2026-10-14

·医药代表

【内部招聘1419】新增市场推广经理、KA、高代等职位！济民可信、恒瑞、智翔金泰、济生堂、托毕西药业…

邮件标题注明：应聘（××企业）职位-姓名（微信mrclub推荐）字样。也欢迎分享给你身边需要寻找新的机会的朋友~ 01 企业官方全国内招岗位（按近期发布时间排序）翰森代谢 | 翰森免疫 | 首药控股拜耳 | 百济神州 02 以下职位由相关药企销售经理根据自己区域岗位需求提供，每周更新2~3次，请自行甄选，有意向者请投递简历至各职位接收邮箱。 --------10月14日新增职位-------- | 济民可信【部门】山东平台【职位】医学信息沟通专员【产品】肾病+呼吸等相关产品【区域】济宁聊城潍坊青岛【优势】薪酬佳，待遇好，福利全【职位要求】1、本科及以上学历；2、医药相关专业；3、有肾内、呼吸2年以上经验和资源，善于沟通⭐ 【简历投递】chenjianwen_jmkx@qq.com | 智翔金泰【公司】上市公司，自免领域特药新产品【岗位】代表，高代，客户经理【地点】大同，太原【产品类型】1）金立希（赛立奇单抗，全人源IL-17A抑制剂），1类新药中国原研中国造；2）公司管线强劲，未来多个适应症及产品上市，自免管线突出，机会多空间大；3）国谈医保，双适应症，潜力巨大【候选人要求】1）内外资企业特药销售管理经验2年及以上；2）皮肤科/风湿科领域推广经验者，Top 优先；3）具备高自驱力、坚韧度、区域开拓能力及学习能力。【薪酬福利】 1）薪酬福利对标一线外企； 2）机会与挑战并存【简历投递】liyunming2026@163.com | 北京托毕西药业有限公司【职位1】市场推广经理（1名），更多职位见上期【负责区域】北京市场【负责产品】巴曲酶注射液【职位要求】1.医学、药学相关专业；2.有两年以上销售/推广/管理工作经验；3.学习能力强，发展意愿强烈；4.有抗凝、抗板类药物销售经验者优先；有神经内科、内分泌科相关资源者优先。【薪资待遇】基础薪酬+月度奖金+年度奖金+福利【简历投递】944124@163.com | 四川济生堂药业有限公司【岗位】医学信息专员【负责区域】南通、盐城各1名【负责产品】舒肝解郁胶囊，独家品种，国家基药【人员要求】1.性格开朗内驱力强；2.勤奋.踏实执行力强；3.有中枢神经线推广工作经验最佳；4.合规转型推广经验优先；5.36岁以下,大专文化，药学、医学相关专业。【薪资待遇】底薪+绩效+五险一金+奖金【简历投递】yuzhihui003@126.com 近期面试 | 恒瑞医药【职位】市场准入-KA地区经理【城市】河南·郑州市【岗位职责】1、构建新型院企合作关系，促进产品可及，推动公司业务发展；2、准确了解和分析目标医院的可及政策，推广公司品牌，提升公司的市场影响力，挖掘出政策中的可及业务机会点；3、加强与省内各部门的密切配合,有效整合公司内部资源,共同协作促进产品可及。【任职要求】1、本科及以上学历，医药学相关专业；2、具备五年以上内外资top销售或市场准入岗位工作经验且有产品独立开发经验;有地区经理等管理岗位经验者优先。【联系方式】18310100784（微信同号） --------10月12日新增职位-------- | 三生制药集团【招聘岗位】关键客户部经理（KA）【工作地点】BASE 福建福州【岗位要求】1. 善于大客户沟通及管理，强执行力，自律敬业，有责任心和学习能力；2. 有KA领域经验或者DM管理经理2年以上，年龄要求85后；3.药学、医学相关专业本科学历【简历投递】13226613642@163.com 近期安排面试。欢迎大家转发[抱拳][抱拳] | 海思科新产品扩招[庆祝] 【公司】海思科镇痛事业部【岗位】地区经理1名、专员多位【区域】广州+广州外围城市，广西【产品】26年新国谈，1类创新药，安瑞克芬，已准入终端，百亿级镇痛蓝海市场【岗位情况】奖金行业前10%，上量为主➕开发【要求】1、大专及以上学历，医药相关；2、积极正向、结果导向、抗压力强、学习能力强；3、肝胆、胃肠、泌尿外科、妇科相关领域客户资源优先【简历投递】357798896@qq.com | 中美华东团队招人啦[庆祝][庆祝][庆祝] 【岗位】（高级）医药代表【区域】广州市皮肤病医院，中山大学附属第六医院各1人【负责产品】乌司奴单抗【产品优势】最核心医院区域，全球百亿美金产品国内首仿，国谈身份无集采风险【要求】1⃣本科及以上学历（医药学类相关专业优先）；2⃣皮肤，消化或特药推广经验；3⃣工作积极主动，有团队合作意识，有较强的沟通能力和学习能力。【公司文化】文化专注做事不内卷，不搞形式主义，沟通简单高效，新产品独立产品线，晋升机会多。【待遇】看齐一线外企薪资，最高可匹配外企专员title底薪，外企标准五险一金，奖金政策好。【简历投递】gzyzhidongye@163.com 【电话微信】18826411055 欢迎推荐，欢迎转发👏👏👏 | 北京托毕西药业有限公司【职位1】地区经理（2名）【职位2】医学信息沟通专员（多名）【负责区域】北京市场【负责产品】巴曲酶注射液【职位要求】1.医学、药学相关专业；2.有两年以上销售/推广/管理工作经验；3.学习能力强，发展意愿强烈；4.有抗凝、抗板类药物销售经验者优先；有神经内科、内分泌科相关资源者优先。【薪资待遇】基础薪酬+月度奖金+年度奖金+福利【简历投递】944124@163.com | 纽迪希亚【区域】肇庆、云浮市场【岗位】医药信息专员【要求】1）有重症、神内外领域或外企经验优先。2）认可专业化学术推广，有较好的专业推广经验。3）诚实守信，有较强团队意识，积极热情，学习能力强。4）公司产品有较好的竞争优势。5）该职位将提供有竞争力的薪资与福利待遇。【简历投递】gdyypp@163.com 【备注】产品专业，市场优质。欢迎大家积极推荐，近期面试！[玫瑰][玫瑰] --------10月9日新增职位-------- | 外企TOP制药企业【产品】新上市产品（罕见病）-奥泽悦【职级】销售主管/(高级)客户专员（一线代表）【base】上海、南通，扩招岗位【特点】1，全球首创，中国首个获批且唯一具有1型发作性睡病适应症的对因治疗的药物；2，罕见病赛道；3，公司战略产品。【要求】1，罕见病，肿瘤特药外企销售经验优先；2，大客户管理能力强，成熟度和独立性好。【简历投递】haiyan.gao@takeda.com 欢迎推荐及自荐，具体沟通，直招岗位HR直接面试，流程快。 | 智翔金泰【公司】科创板上市企业（688443），中国创新驱动型生物制药龙头，聚焦自身免疫性疾病、感染性疾病、肿瘤三大领域，具备从抗体发现到商业化实施的全产业链能力。2026年Q1营收同比233.63%，超400人自免商业化团队，两款核心产品正处市场放量与上市冲刺的关键节点。【岗位】代表/高代/客户经理：3名【城市】南宁、海口、梧州【候选人要求】1、全日制本科优先，医药相关专业；2、皮肤科/风湿科1年以上销售经验，熟悉PoS/AS诊疗路径；3、强沟通、高自驱【薪资福利】薪酬福利超一线外企、远超同类的奖金政策，晋升空间大。【简历投递】944412519@qq.com（备注：岗位+区域） 🚩欢迎转发、推荐！ | 费森尤斯卡比【公司】世界500强【职位】CSO渠道项目拓展主管【地点】武汉、西安各1名【主要工作职责】1.基于市场洞察制定区域策略，全流程管控项目目标落地达成；2.开展合作客户的开发与维护、谈判及签约工作，监督项目流程并解决执行中的关键问题；3.收集市场信息，联动内部部门协同解决准入、提升及项目推进问题；4.协同合作公司日常人员管理、绩效追踪与协同拜访，通过带教赋能提升团队学术开拓能力；【任职要求】1.本科及以上学历，临床医学、药学、护理、生物制药等医药相关专业；2.两年及以上医药行业推广或项目管理相关经验；3.年龄35岁以内【简历投递】394070059@qq.com | 欧康维视生物医药（上海）有限公司【岗位】医学信息推广专员【岗位市场】杭州，温州，南昌【负责产品】眼科产品【候选人要求】1.医学、生物、市场营销相关专业本科以上学历；2.外企1-2年药品销售经验者优先；3.踏实靠谱，具有良好学习能力、抗压能力、综合素质优秀【岗位优势】广阔的职业发展前景，后续在研多个重磅产品【福位福利】外企底薪待遇+补贴+节日补贴+五险一金+奖金【简历投递】13560020683@163.com 欢迎大家投递简历或推荐，谢谢！ | 某生物创新药企【公司】生物创新药企，管线内多款自研创新生物药【岗位1】地区经理/高级地区经理；【城市】安徽省（合肥）【岗位2】医药代表/高级医药代表/专员【城市】江苏省（南京）【任职要求】1、大专及以上学历，医药相关专业，医药备案（必须）；2、2年及以上心血管领域从业经验(必须）；3、有较强的团队管理能力，平台搭建能力（地区经理）【简历投递】55889243@qq.com（请在邮件标题注明投递岗位）欢迎转发推荐！ --------9月28日新增职位-------- | 一品红药业集团【公司】一家集药品研发、生产、销售于一体的创新型上市企业，在儿童健康领域拥有多个独家产品，在痛风领域自主研发，AR882是全球新的重磅产品，现公司开始搭建儿感领域自营商业化团队[庆祝] 【职位】（高级）医学信息沟通专员【Base地】上海多个核心岗位在招【要求】有儿科、耳鼻喉、感染，风湿等慢病或普药领域推广开发经验者优先，过往有外企背景优先，学术专业推广能力强。【专业】本科，医药相关专业毕业（必需）。【亮点】1.一线外企管理层架构，管理规范化，系统化；2.产品管线丰富，多款重磅自研产品陆续上市，发展潜力大；3.具备竞争力的薪酬福利体系【简历投递】373154576@qq.com 【备注】收到简历后12小时内安排面试 | 郑州元溯医药【岗位】市场推广专员实习生/医学推广专员实习生【Base地】郑州【负责产品】1.国谈乳腺癌原研创新药；2.国谈肺癌原研创新药；3.国谈代谢性疾病创新药；4.国谈感染性疾病创新药【工作内容】1.临床学术协访及推广辅导；2.各类学术活动组织召开；3.各类医学药学项目执行；4.KOL客户对接及协同管理【候选人要求】1.专科及以上学历，医药相关专业；2.2027年毕业生，有较强的执行力；3.积极主动，需要出差，稳定性好；4.对标头部企业的薪资待遇，无需垫资，实习结束后直接留用【电话/微信】闫总：13213193718 --------9月25日新增职位-------- | 费森尤斯卡比【公司】世界500强【职位】CSO渠道项目拓展主管【地点】广州、西安各1名【主要工作职责】1.基于市场洞察制定区域策略，全流程管控项目目标落地达成；2.开展合作客户的开发与维护、谈判及签约工作，监督项目流程并解决执行中的关键问题；3.收集市场信息，联动内部部门协同解决准入、提升及项目推进问题；4.协同合作公司日常人员管理、绩效追踪与协同拜访，通过带教赋能提升团队学术开拓能力；【任职要求】1.本科及以上学历，临床医学、药学、护理、生物制药等医药相关专业；2.两年及以上医药行业推广或项目管理相关经验；3.年龄35岁以内【简历投递】394070059@qq.com --------9月21日新增职位-------- | 外企TOP制药企业【产品】新上市产品（罕见病）-奥泽悦【职级】销售主管/(高级)客户专员（一线代表）【base】南宁/海口--扩招岗位【特点】1，全球首创、中国首个获批且唯一具有1型发作性睡病适应症的对因治疗的药物；2，罕见病赛道；3，公司战略产品。【要求】1，罕见病，肿瘤特药外企销售经验优先；2，大客户管理能力强，成熟度和独立性好。【简历投递】529852864@qq.com 欢迎推荐及自荐，具体沟通，直招岗位HR直接面试，流程快。 --------9月19日新增职位-------- | 武田中国【部门】罕见病【岗位级别】客户专员/主管【城市】合肥，温州扩招扩招扩招！！！【产品】奥泽悦（全球唯一食欲素2受体激动剂，用于1型发作性睡病），全球同步提交申请，中国首个获批的进口创新药！！！【薪资】面议【Base地】合肥1个（合肥+外围），温州1个（温州+周边）【岗位要求】1、本科及以上学历，医学、药学等相关专业毕业；2、既往业绩优秀，良好大客户管能力+学习能力，top sales，呼吸领域优先考虑；【简历投递】telong.chen@takeda.com 有意向的小伙伴请直接投递或推荐简历至邮箱 📪[玫瑰][玫瑰] --------9月14日新增职位-------- | 安进(Amgen) 【公司】全球领先的生物医药公司【部门】持续卓越的CVBU北三区团队，因业务快速拓展新增岗位【职位】高级生物医药代表/生物医药代表【区域】内蒙鄂尔多斯市【产品】瑞百安等【科室】心血管，神经内科，内分泌等科室。【基本要求】1.具有医学、药学或相关专业大学专科及以上学历；2.掌握所推广药品的药理毒理、功能主治或适应症、联合用药、不良反应、禁忌症和注意事项等知识；3.经公司培训并考核合格；4.不得存在法律法规禁止从事医药代表工作的情形；【品德及能力】诚实正直，能够做正确的事，积极主动、思维正向，做事节奏快、不拖延，极强的进取心，目标感强。较强的学习能力，具备客户选定、深度拜访、科室会演讲、KOL管理、会议组织等能力。【简历投递】n3amgenzp@126.com | 费森尤斯卡比【部门】肠内肠外营养【职位】CSO渠道项目拓展主管【地点】广州。【人数】1名【主要工作职责】1.基于市场洞察制定区域策略，全流程管控项目目标落地达成；2.开展合作客户的开发与维护、谈判及签约工作，监督项目流程并解决执行中的关键问题；3.收集市场信息，联动内部部门协同解决准入、提升及项目推进问题；4.协同合作公司日常人员管理、绩效追踪与协同拜访，通过带教赋能提升团队学术开拓能力；【任职要求】1.本科及以上学历，临床医学、药学、护理、生物制药等医药相关专业；2.两年及以上医药行业推广或项目管理相关经验；3.年龄35岁以内【简历投递】394070059@qq.com --------9月11日新增职位-------- | 费森尤斯卡比【部门】肠内肠外营养【职位】CSO渠道项目拓展主管【地点】广州、合肥各1名【工作职责】1.基于市场洞察制定区域策略，全流程管控项目目标落地达成；2.开展合作客户的开发与维护、谈判及签约工作，监督项目流程并解决执行中的关键问题；3.收集市场信息，联动内部部门协同解决准入、提升及项目推进问题；4.协同合作公司日常人员管理、绩效追踪与协同拜访，通过带教赋能提升团队学术开拓能力；【任职要求】1.本科及以上学历，临床医学、药学、护理、生物制药等医药相关专业；2.两年及以上医药行业推广或项目管理相关经验；3.年龄35岁以内【简历投递】394070059@qq.com | 安进【公司】美国生物制药巨头【岗位】医药代表【区域】广西：南宁、柳州【负责产品】依洛尤单抗注射液（瑞百安）等产品【岗位要求】90后，医药相关专业，本科以上学历，外企经验两年以上，有心内领域经验优先【覆盖科室】心内科/神内科/骨科等【简历投递】43490220@qq.com --------9月8日新增职位-------- | 齐鲁制药【部门】苏北分公司【岗位】学术推广专员【工作区域】泰州市区、南通市区【负责产品】注射用曲妥珠单抗、帕妥珠单抗注射液、TAS-102、伊鲁阿克片等即将上市甲磺酸氘申艾替尼等【要求】1、大专及以上学历，药学、临床医学、生物医药等相关专业优先；2、1-3年肿瘤/乳腺领域经验者优先；3、有较强自我驱动力；4、具备较强的沟通能力及学术推广技巧，有较强抗压能力【简历投递】727000262@qq.com Tips：岗位好，奖金高，市场良性欢迎投递 | 安进【公司】美国生物制药巨头【岗位】医药代表【区域】湖南：长沙、岳阳、邵阳【负责产品】依洛尤单抗注射液（瑞百安）等产品【岗位要求】90后，医药相关专业，本科以上学历，外企经验两年以上，有心内领域经验优先【覆盖科室】心内科/神内科/骨科等【简历投递】43490220@qq.com --------9月6日新增职位-------- | 安进【公司】美国生物制药巨头【岗位】医药代表【区域】江苏扬州➕泰州【负责产品】依洛尤单抗注射液（瑞百安）等产品【岗位要求】90后，医药相关专业，本科以上学历，外企经验两年以上，有心内领域经验优先【覆盖科室】心内科/神内科/骨科等【简历投递】sunyixiong1991@126.com 欢迎推荐！👏👏👏 | 武田中国【部门】武田罕见病: 遗传性血管性水肿【岗位】客户专员/主管【Base地】深圳【产品】达泽优/飞泽优【治疗领域】消化、过敏、皮肤等，市场独家双国谈医保产品，不可多得的可防可治罕见病领域【岗位要求】1、本科及以上学历，医学、药学等相关专业毕业；2、既往业绩优秀，具备大客户管理经验，积极主动，学习能力优秀，学术推广要求高，top sales优先；3、消化、皮肤、过敏相关领域经验，有罕见病/特药/慢病经验优先（非大外企勿扰）【简历投递】xiaoqin.yu@takeda.com 有意向投身罕见病事业的小伙伴请直接投递或推荐简历 ※ 查询如何在MRCLUB发布招聘信息请回复“招聘指南”获取。（医药代表微信号：mrclub）获取更多职位信息还可以关注下面公众号：

2026-10-13

·BioSpace

CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer

DALLAS, Oct. 13, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. A highly accomplished biopharmaceutical executive with more than 20 years of commercial leadership experience, Ms. Kalofonos will lead the Company's commercial strategy and execution as CG Oncology advances toward the potential launch of cretostimogene grenadenorepvec and continues to establish itself as a leader in bladder cancer. "Isabel’s appointment reflects our commitment to ensuring we are well positioned to bring cretostimogene to as many patients as possible upon approval," said Arthur Kuan, Chairman and Chief Executive Officer of CG Oncology. "As we prepare for a potential first commercial launch, we are making deliberate investments in experienced leaders who have successfully built commercial organizations, developed differentiated strategies, and delivered product launches at scale. Isabel brings an outstanding track record of commercial execution across multiple therapeutic areas and stages of growth, and we are confident her expertise will be instrumental as we prepare to deliver on the full potential of cretostimogene." Ms. Kalofonos brings more than 20 years of experience driving successful launches and commercial execution, helping bring innovative therapies to patients at scale across the biotechnology and pharmaceutical industries. Most recently, she served as Chief Commercial Officer of Crinetics Pharmaceuticals (acquired by Vertex Pharmaceuticals), where she played a key role in the company’s transition to the commercial stage, helping to drive the successful launch of PALSONIFY™ (paltusotine) and advance commercial planning across the pipeline. Prior to Crinetics, Ms. Kalofonos served as Chief Commercial Officer at ImmunoGen (acquired by AbbVie), where she led the successful launch of ELAHERE® (mirvetuximab soravtansine) in ovarian cancer. Earlier in her career, Ms. Kalofonos served as Senior Vice President and Global Head of the Prescription Business Unit at Galderma, where she oversaw the build-out of the business unit and pre-launch preparations for NEMLUVIO® (nemolizumab). She also served as Vice President and Head of the Hereditary Angioedema Franchise at Takeda Pharmaceuticals (formerly Shire), leading a multi-billion-dollar business and the successful global launch of TAKHZYRO® (lanadelumab‑flyo). Throughout her career, she has built and led high-performing global commercial organizations across oncology, immunology, rare diseases, and neurology. Ms. Kalofonos holds an M.B.A. in Entrepreneurship and Marketing from Babson College and a bachelor's degree in Industrial Engineering from Pontificia Universidad Javeriana. "CG Oncology is entering an exciting and transformative period, and I am thrilled to join the company at such a pivotal time," said Isabel Kalofonos. "The clinical data generated to date for cretostimogene, the significant unmet need that remains for patients with bladder cancer, and the passion of the CG Oncology team make this a truly compelling opportunity. Having spent much of my career preparing companies for launch and building commercial organizations, I look forward to hitting the ground running, partnering across the organization, and helping ensure we are ready to successfully bring cretostimogene to patients." About Cretostimogene Grenadenorepvec Cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy that has been studied in a clinical development program, which includes more than 400 patients with Non-Muscle Invasive Bladder Cancer (NMIBC). This program includes two Phase 3 clinical trials: BOND-003 for high-risk BCG-unresponsive NMIBC and PIVOT-006 for intermediate-risk NMIBC. Cretostimogene has received FDA Fast Track and Breakthrough Therapy designations. CG Oncology also has a Phase 2 trial, CORE-008, evaluating the safety and efficacy of cretostimogene in high-risk NMIBC. Additionally, we have initiated an Expanded Access Program for cretostimogene in North America for patients who are unresponsive to BCG and meet certain program eligibility requirements. Cretostimogene is an investigational candidate, and its safety and efficacy have not been established by the FDA or any other health authority. About CG Oncology CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: . Forward-Looking Statements CG Oncology cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to, statements regarding the potential approval and commercial launch of cretostimogene, the timing, progress and success of our commercial launch preparations and commercialization activities, our ability to build and execute our commercial strategy and establish the infrastructure necessary to support a potential commercial launch, the anticipated contributions of our Chief Commercial Officer, our ability to bring cretostimogene to patients, if approved, the potential therapeutic and commercial benefits of cretostimogene, and our ability to advance our position in the treatment of bladder cancer. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: the timing and outcome of regulatory review of cretostimogene and the possibility that regulatory approval may be delayed, limited or not obtained, uncertainties regarding the timing and success of our commercial launch preparations and commercialization activities, our ability to establish, scale and maintain an effective commercial infrastructure, the scope of any approved indication or labeling for cretostimogene, the rate and degree of market acceptance of cretostimogene, if approved, by patients, healthcare providers and payors, our ability to obtain and maintain adequate pricing, coverage and reimbursement, our ability and the ability of our third-party manufacturers and suppliers to manufacture and supply sufficient quantities of cretostimogene for commercial use, competition from existing and future therapies, unexpected adverse side effects or inadequate efficacy of cretostimogene that may limit its development, regulatory approval or commercialization, our dependence on third parties in connection with manufacturing, shipping, clinical testing and commercialization activities, our ability to attract and retain key personnel, and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K and other filings that we make with the SEC from time to time (which are available at ). You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contacts: Media Sarah Connors Vice President, Communications and Patient Advocacy, CG Oncology sarah.connors@cgoncology.com Investor Relations Megan Knight Vice President, Investor Relations, CG Oncology megan.knight@cgoncology.com

高管变更临床2期快速通道突破性疗法

100 项与拉那利尤单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11094	拉那利尤单抗	B06AC05	DB14597

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
遗传性血管性水肿	美国	Takeda Pharmaceuticals U.S.A., Inc.	2018-08-23

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
血管性水肿	临床3期	美国	Shire Plc	2021-02-05
血管性水肿	临床3期	日本	Shire Plc	2021-02-05
血管性水肿	临床3期	加拿大	Shire Plc	2021-02-05
血管性水肿	临床3期	法国	Shire Plc	2021-02-05
血管性水肿	临床3期	德国	Shire Plc	2021-02-05
血管性水肿	临床3期	匈牙利	Shire Plc	2021-02-05
血管性水肿	临床3期	意大利	Shire Plc	2021-02-05
血管性水肿	临床3期	荷兰	Shire Plc	2021-02-05
血管性水肿	临床3期	波兰	Shire Plc	2021-02-05
血管性水肿	临床3期	西班牙	Shire Plc	2021-02-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04130191 (ENABLE, AAAAI2026)	N/A	遗传性血管性水肿	27	Lanadelumab	顧積餘壓範蓋衊餘餘餘(遞窪憲憲糧鏇齋衊簾鏇) = 餘構淵憲鹽襯鑰範膚繭壓廠簾構憲獵襯廠醖衊 (齋醖獵衊窪醖襯齋製糧, 0.2) 更多	积极	2026-02-27
AAAAI2026	N/A	遗传性血管性水肿	36	Lanadelumab	繭築選憲鏇鬱鑰窪壓構(遞艱觸襯選蓋壓蓋壓製) = 夢構選選獵齋觸廠觸顧觸齋鹹網獵廠廠鑰淵衊 (鹹製鏇願顧簾襯蓋製襯 ) 更多	积极	2026-02-27
AAAAI2026	N/A	遗传性血管性水肿	499	Takhzyro	積憲築網醖壓鑰蓋範衊(壓齋壓鏇夢鑰糧憲餘繭) = 遞夢範餘鬱範製衊遞鹹鹽淵製鹹壓夢憲觸窪憲 (壓蓋鑰鏇獵蓋獵構膚餘 ) 更多	不佳	2026-02-27
NCT05297786 (Hinder, CTgov)	临床2期	终末期肾脏病 \| 肾病 \| 透析性低血压	28	Lanadelumab (Lanadelumab)	襯鬱獵齋鹽蓋憲範顧構(壓簾壓鹹網夢鏇構願夢) = 淵憲衊製網鹹鹹鑰製鏇醖夢積衊憲鏇襯築鏇繭 (積蓋製遞製夢鑰積鑰蓋, 36.3) 更多	-	2026-01-20
				Placebo (Placebo)	襯鬱獵齋鹽蓋憲範顧構(壓簾壓鹹網夢鏇構願夢) = 簾製憲衊窪壓壓齋壓鏇醖夢積衊憲鏇襯築鏇繭 (積蓋製遞製夢鑰積鑰蓋, 28.8) 更多
NCT03845400 (EMPOWER, Pubmed \| Adv Ther)	临床4期	遗传性血管性水肿 C1 inhibitor deficiency type 1	109	Newly treated with Lanadelumab	衊艱繭鹽顧夢構鬱築顧(憲簾構遞壓願窪鑰製鬱) = 膚構繭積齋餘築選簾鑰鏇選遞鹽構築範膚淵夢 (醖選齋繭積願糧夢襯糧, 0.34 ~ 2.50)	积极	2025-08-01
				Established on Lanadelumab	衊艱繭鹽顧夢構鬱築顧(憲簾構遞壓願窪鑰製鬱) = 鹹窪糧簾醖繭艱網網窪鏇選遞鹽構築範膚淵夢 (醖選齋繭積願糧夢襯糧, 0.10 ~ 0.30)
NCT04444895 \| NCT04206605 (CASPIAN Study, Pubmed \| Front Immunol)	临床3期	遗传性血管性水肿Ⅲ型	77	Lanadelumab 300 mg every 2 weeks	鏇艱窪網壓廠壓範觸觸(膚醖糧艱製夢齋齋構繭) = 衊鹽醖鏇鹽襯夢鹹願廠顧遞觸觸顧夢鬱鑰膚醖 (憲鏇襯餘繭積願遞觸壓 )	-	2025-05-21
				Placebo	鏇艱窪網壓廠壓範觸觸(膚醖糧艱製夢齋齋構繭) = 壓願窪淵築窪遞繭構鬱顧遞觸觸顧夢鬱鑰膚醖 (憲鏇襯餘繭積願遞觸壓 )
NCT04130191 \| NCT03845400 (Phase 4 studies (EMPOWER, ENABLE), Pubmed \| Pediatr Allergy Immunol)	临床4期	遗传性血管性水肿	-	Lanadelumab 300 mg	簾醖願襯築構衊繭鑰網(鑰鹹衊獵衊獵廠築顧淵) = Nine new patients reported 42 TEAEs, mostly mild/moderate in severity, with 3 TEAEs reported as serious. Seven established patients reported 12 TEAEs (all mild/moderate and non‐serious). No TEAEs were related to lanadelumab. 夢製獵鹽窪鑰膚鏇鑰製 (廠淵餘淵淵夢淵鬱構膚 )	积极	2025-04-01
AAAAI2025	N/A	遗传性血管性水肿	252	Lanadelumab 300 mg biweekly	艱艱醖製廠窪範獵壓糧(蓋艱廠淵夢蓋憲壓選膚) = 糧遞鬱觸構顧製蓋顧顧齋範網醖鑰憲夢艱積鹹 (鬱鑰艱憲顧構壓憲壓簾 ) 更多	积极	2025-02-28
				Placebo	艱艱醖製廠窪範獵壓糧(蓋艱廠淵夢蓋憲壓選膚) = 夢範構淵鹹選範醖遞製齋範網醖鑰憲夢艱積鹹 (鬱鑰艱憲顧構壓憲壓簾 )
AAAAI2025	N/A	遗传性血管性水肿	158	Stanozolol	蓋糧夢構齋齋鏇醖糧願(鑰築鬱觸蓋遞餘願鹹艱) = 構壓構醖壓觸餘夢鹹膚窪廠淵觸衊選鏇糧齋築 (範襯鹹築積構鹽蓋繭艱 ) 更多	积极	2025-02-28
				Danazol	蓋糧夢構齋齋鏇醖糧願(鑰築鬱觸蓋遞餘願鹹艱) = 鹹鹹夢鬱願淵餘顧網襯窪廠淵觸衊選鏇糧齋築 (範襯鹹築積構鹽蓋繭艱 ) 更多
AAAAI2025	N/A	遗传性血管性水肿	242	Lanadelumab	網獵網積齋鏇遞網憲鹽(糧糧鹽製遞遞選壓蓋網) = 艱壓願壓艱觸製鬱觸憲築餘襯艱膚築糧獵築膚 (網鹽網醖餘醖醖廠壓鬱 ) 更多	积极	2025-02-28
				Berotralstat	網獵網積齋鏇遞網憲鹽(糧糧鹽製遞遞選壓蓋網) = 醖淵鹹艱獵選廠膚鹹獵築餘襯艱膚築糧獵築膚 (網鹽網醖餘醖醖廠壓鬱 ) 更多